Abstracts tagged "COVID-19"

Abstract Number: 1933 • ACR Convergence 2022
PECOS (Pediatric SARS-CoV-2 MIS-C Long-term Outcomes Study): Preliminary Results
Gina Montealegre Sanchez¹, Roberta DeBiasi², Lauren Arrigoni², Kevin Rubenstein³, Jason Liang⁴, James Bost², Marcin Gierdalski², Max Wolff³, Mallory Barrix², Maureen Edu², Saira Huq², Shera Weyers³, Patricia Bandettini⁵, Dorothy Bulas², Tom Burklow⁶, Marcus Chen⁵, Sanchita Das⁶, Robin Dewar³, Joseph Fontana⁵, Ashraf Harahsheh², Linda Herbert², Anastassios Koumbourlis², Andrew Lipton⁵, Laura Olivieri², Dinesh Pillai², Vandana Sachdev⁵, Craig Sable², Audrey Thurm⁷, Evrim Turkbey⁶, Alexandra Yonts², Jonathan Zember², Eric Vilain², Meghan Delaney², Luigi Notarangelo⁴, David Wessel⁸ and Karyl Barron⁴, ¹NIAID/NIH, Garrett Park, MD, ²Children's National Hospital, Washington, DC, ³Frederick National Laboratory for Cancer Research, Frederick, MD, ⁴NIAID/NIH, Bethesda, MD, ⁵NHLBI/NIH, Bethesda, MD, ⁶CC/NIH, Bethesda, MD, ⁷NIMH/NIH, Bethesda, MD, ⁸Children's National Hospital, Washington, MD
Background/Purpose: The long-term complications of SARS-CoV-2 and MIS-C in children are unknown. PECOS, a joint study at the National Institutes of Health (NIH) Clinical Center…
Abstract Number: 2249 • ACR Convergence 2022
Impact of Interstitial Lung Disease on COVID-19 Severity Among Patients with Rheumatoid Arthritis: A Multicenter Comparative Study
Gabriel Figueroa Parra¹, Emily Gilbert², Maria Valenzuela Almada¹, Sebastian Vallejo¹, Matthew Neville³, Naomi Patel⁴, Claire Cook⁵, Xiaoqing Fu⁵, Ramla Hagi⁵, Gregory McDermott⁶, Michael Dilorio⁶, Lucy Masto⁶, Kathleen Vanni⁶, Emily Kowalski⁶, Grace Qian⁶, Zachary Wallace⁵, Ali Duarte-Garcia¹ and Jeffrey Sparks⁷, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Jacksonville, FL, ³Mayo Clinic, Phoenix, AZ, ⁴Massachusetts General Hospital, Sale Creek, TN, ⁵Massachusetts General Hospital, Boston, MA, ⁶Brigham and Women's Hospital, Boston, MA, ⁷Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Rheumatoid arthritis (RA) has been associated with severe COVID-19, but few studies have investigated outcomes in RA phenotypes such as interstitial lung disease (RA-ILD),…
Abstract Number: 0211 • ACR Convergence 2022
Determinants of COVID-19 Vaccine Hesitancy in a Predominantly Black Population with Cutaneous Lupus Erythematosus
Sophia Lutgen¹, S. Sam Lim², Laura D. Aspey², Gaobin Bao³, Charmayne Dunlop-Thomas², Jessica N. Williams² and Cristina Drenkard², ¹Mount Sinai Morningside-West, New York, NY, ²Emory University, Atlanta, GA, ³Emory University School of Medicine, Atlanta, GA
Background/Purpose: Due to demographic and disease-related factors, patients with lupus are deemed to be more vulnerable to COVID-19 infection than the general population, but they…
Abstract Number: 0702 • ACR Convergence 2022
Fourth SARS-CoV-2 Vaccine Dose in Rituximab Treated Patients: An Open Label Extension Study
Daniel Mrak¹, Elisabeth Simader¹, Daniela Sieghart¹, Peter mandl², Helga Radner¹, Thomas Perkmann³, Helmuth Haslacher³, Margareta Mayer⁴, Maximilian Koblischke⁴, Philipp Hofer⁵, Lisa Göschl¹, Felix Kartnig¹, Thomas Deimel⁶, Andreas Kerschbaumer⁶, Thomas Hummel¹, Barbara Kornek⁶, Renate Thalhammer³, Karin Stiasny⁴, Stefan Winkler⁷, Josef Smolen⁶, Judith Aberle⁴, Daniel Aletaha⁸, Leonhard Heinz¹ and Michael Bonelli¹, ¹Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, ²Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Wien, Austria, ³Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria, ⁴Center for Virology, Medical University of Vienna, Vienna, Austria, ⁵Department of Pathology, Medical University of Vienna, Vienna, Austria, ⁶Medical University of Vienna, Vienna, Austria, ⁷Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria, ⁸Medical University Vienna, Wien, Austria
Background/Purpose: Humoral immune response to COVID-19 vaccination is vastly diminished in B-cell depleted patients, resulting in lower antibody titers in patients with a potential higher…
Abstract Number: 0769 • ACR Convergence 2022
Heterologous Vector versus Homologous mRNA COVID-19 Booster Vaccination in Non-seroconverted Immunosuppressed Patients: A Randomized Controlled Trial
Daniela Sieghart¹, Daniel Mrak¹, Elisabeth Simader¹, Selma Tobudic², Helga Radner¹, Peter Mandl³, Lisa Göschl¹, Maximilian Koblischke⁴, Nikolaus Hommer⁵, Lukas Hartl⁶, Philipp Hofer⁷, Felix Kartnig¹, Thomas Hummel¹, Andreas Kerschbaumer³, Thomas Deimel³, Antonia Puchner¹, Renate Thalhammer⁸, Andreas Zuckermann⁹, Karin Stiasny⁴, Thomas Perkmann⁸, Helmuth Haslacher⁸, Markus Zeitlinger⁵, Ursula Wiedermann¹⁰, Judith Aberle⁴, Daniel Aletaha¹¹, Leonhard Heinz¹ and Michael Bonelli¹, ¹Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, ²Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria, ³Medical University of Vienna, Vienna, Austria, ⁴Center for Virology, Medical University of Vienna, Vienna, Austria, ⁵Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria, ⁶Division of Gastroenterology, Medical University of Vienna, Vienna, Austria, ⁷Department of Pathology, Medical University of Vienna, Vienna, Austria, ⁸Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria, ⁹Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria, ¹⁰Institute of Specific Prophylaxis and Tropical Medicine, Center of Pathophysiology, Infectiology & Immunology, Medical University Vienna, Vienna, Austria, ¹¹Medical University Vienna, Wien, Austria
Background/Purpose: Patients under immunosuppressive therapy have a high risk for severe COVID-19 disease courses. However, efficacy of vaccination and therefore the right vaccination strategy remains…
Abstract Number: 0792 • ACR Convergence 2022
Post-mRNA Vaccine Flares in Autoimmune Inflammatory Rheumatic Diseases: Results from the COronavirus National Vaccine Registry for ImmuNe Diseases SINGapore (CONVIN-SING)
Margaret Ma¹, Amelia Santosa¹, Kok Ooi Kong², Chuanhui Xu², Gim Gee Teng¹, Johnston GX Tang², Anselm Mak³, Frank Tay¹, Victoria WW Ng⁴, Joshua ZE Koh⁴, Warren Fong⁵, Li-Ching Chew⁶, Andrea Low⁷, annie law⁸, Yih Jia Poh⁸, Siaw Ing Yeo⁶, Ying Ying Leung⁹, Wei-Rui Goh⁶, Nur Emilia Roslan¹⁰, Tyng Yu Chuah¹⁰, Stanley Angkodjojo¹¹, Thaschawee Arkachaisri¹², Kai Liang Teh¹³, Kee Fong Phang¹⁴, Melonie Sriranganathan¹⁵, teck Choon Tan¹⁶, Peter Cheung¹ and Manjari Lahiri¹, ¹National University Hospital, Singapore, Singapore, ²Tan Tock Seng Hospital, Singapore, Singapore, ³Division of Rheumatology, Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, ⁴National University of Singapore, Singapore, Singapore, ⁵Singapore Health Services Pte Ltd (SHS), Singapore, Singapore, ⁶Singapore General Hospital, Singapore, Singapore, ⁷Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore, ⁸SingHealth, Singapore, Singapore, ⁹Rheumatology Department, Singapore General Hospital, Singapore, Singapore, ¹⁰Sengkang General Hospital, Singapore, Singapore, ¹¹Sengkang General Hospital / Singhealth, Singapore, Singapore, ¹²KK Women's and Children's Hospital, SingHealth, Singapore, Singapore, ¹³KK Women's and Children's Hospital, Singapore, Singapore, ¹⁴Alexandra Hospital, Singapore, Singapore, ¹⁵Changi General Hospital, Singapore, Singapore, ¹⁶Khoo Teck Puat Hospital, Singapore, Singapore
Background/Purpose: Published data suggest no increased rate of flare of autoimmune inflammatory rheumatic diseases (AIIRD) after COVID-19 mRNA vaccination; however, the studies are limited by…
Abstract Number: 0932 • ACR Convergence 2022
Accelerated Waning of Protective Immunity After SARS-CoV-2 mRNA Vaccination in Patients Treated with Biological and Targeted Synthetic Disease Modifying Antirheumatic Drugs
Elisabeth Simader¹, Selma Tobudic², Thomas Deimel³, Peter mandl⁴, Helmuth Haslacher⁵, Thomas Perkmann⁵, Lisa Schneider⁶, Thomas Nothnagl⁷, Helga Radner¹, Florian Winkler⁸, Heinz Burgmann⁸, Karin Stiasny⁹, Gottfried Novacek¹⁰, Walter Reinisch¹¹, Daniel Aletaha¹², Stefan Winkler² and STEPHAN BLUEML¹, ¹Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, ²Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria, ³Medical University of Vienna, Vienna, Austria, ⁴Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Wien, Austria, ⁵Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria, ⁶Department of Internal Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Vienna, ⁷Second Medical Department, Korneuburg-Stockerau Hospital, Lower Austrian Centre for Rheumatology, Stockerau, Austria, ⁸Department of Internal Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Vienna, Austria, ⁹Center for Virology, Medical University of Vienna, Vienna, Austria, ¹⁰Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria, ¹¹Division of Gastroenterology & Hepatology, Medical University of Vienna, Vienna, Austria, ¹²Medical University Vienna, Wien, Austria
Background/Purpose: Little is known about the duration of humoral antibody levels after two SARS-CoV-2 mRNA vaccinations in patients with immunosuppression. During this ongoing global epidemic,…
Abstract Number: 1326 • ACR Convergence 2022
Impact of COVID-19 Severity on Bone Mineral Density, Sarcopenia and Physical Performance Among Older Adults Following Hospitalization: A Pilot Study
Diego Cabrera¹, Clara Wong², Andrew Cohen³, Lauren Ferrante³, Alexandra Hajduk³ and Evelyn Hsieh¹, ¹Section of Rheumatology, Allergy and Immunology, Yale School of Medicine, New Haven, CT, ²Yale School of Public Health, New Haven, CT, ³Yale School of Medicine, New Haven, CT
Background/Purpose: Altered bone mineral density (BMD), muscle mass and physical performance has been associated with adverse outcomes, however, the effect of COVID-19 on the musculoskeletal…
Abstract Number: 1763 • ACR Convergence 2022
Different Humoral but Similar Cellular Responses of Patients with Autoimmune Inflammatory Rheumatic Diseases Under Disease-modifying Anti-rheumatic Drugs After COVID-19 Vaccination
Ioana Andreica¹, Arturo Blazquez-Navarro², Jan Sokolar³, Moritz Anft⁴, Uta Kiltz⁵, Stephanie Pfaender⁶, Elena Vidal Blanco⁷, Timm Westhoff⁸, Nina Babel⁸, Ulrik Stervbo⁹ and Xenofon Baraliakos¹⁰, ¹Rheumazentrum Ruhrgebiet, Ruhr-Universität-Bochum, Herne, Germany, ²Charité Universitätsmedizin Berlin, Berlin Center for Advanced Therapies, Berlin, Germany, ³Rheumazentrum Ruhrgebiet Herne, Ruhr Universität Bochum, Herne, Germany, ⁴Marienhospital Herne - Klinik Mitte Medizinische Klinik I - Gastroenterologie, Nieren- und Hochdruckkrankheiten, Center for Translational Medicine and Immune Diagnostics Laboratory, Medical Department I, Herne and Ruhr-Universit t Bochum, Medical Department I, Bochum, Germany, ⁵Rheumazentrum Ruhrgebiet, Herne, Germany, ⁶Ruhr-Universität Bochum, Medical Department I, Bochum, Germany, ⁷Ruhr-University Bochum, Department of Molecular and Medical Virology, Bochum, Germany, ⁸Marienhospital Herne, Ruhr-University Bochum, Herne, Germany, ⁹Marienhospital Herne - Klinik Mitte Medizinische Klinik I - Gastroenterologie, Nieren- und Hochdruckkrankheiten, Center for Translational Medicine and Immune Diagnostics Laboratory, Medical Department I, Herne and Ruhr-Universität Bochum, Medical Department I, Bochum, Germany, ¹⁰Rheumazentrum Ruhrgebiet Herne, Herne, Germany
Background/Purpose: The interplay between humoral and cellular response after vaccination against SARS-CoV-2 in patients (pts.) with autoimmune inflammatory rheumatic diseases (AIRD) remains unknown. To investigate…
Abstract Number: 1938 • ACR Convergence 2022
Current Approach to COVID-19 and Other Vaccinations in Children with Previous Multisystem Inflammatory Syndrome (MIS-C): An International Survey
Francesca Minoia¹, Federica Lucioni¹, Merav Heshin-Bekenstein², Sebastiaan Vastert³, Christoph Kessel⁴, Yosef Uziel⁵, Lovro Lamot⁶, Nicola Ruperto⁷, Marco Gattorno⁸, Claudia Bracaglia⁹ and Natasa Toplak¹⁰, ¹Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy, ²Dana Dwek Children's Hospital, Tel Aviv Medical Center Israel, Binyamina, Israel, ³Pediatric Rheumatology & Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁴Department of Pediatric Rheumatology & Immunology, WWU Medical Center (UKM), Münster, Germany, ⁵Meir Medical Center, Kfar Saba; Sackler School of Medicine, Tel Aviv University, Kfar Saba, Israel, ⁶University Hospital Center Zagreb, Zagreb, Croatia, ⁷IRCCS Istituto Giannina Gaslini; PRINTO, Clinica Pediatrica e Reumatologia, Genova, Italy, ⁸Pediatric Clinic and Rheumatology Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy, ⁹Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy, ¹⁰University Children's Hospital, University Medical Centre, Ljubljana, Slovenia
Background/Purpose: Following the Coronavirus Disease-19 (COVID-19) pandemic outbreaks, the hyperinflammatory condition termed Multisystem Inflammatory Syndrome in Children (MIS-C) has become a healthcare issue worldwide. Since…
Abstract Number: 2272 • ACR Convergence 2022
Temporal Trends in COVID-19 Outcomes Among Patients with Systemic Autoimmune Rheumatic Diseases: From the First Wave to Omicron
Yumeko Kawano¹, Naomi Patel², Xiaosong Wang¹, Claire Cook³, Kathleen Vanni¹, Emily Kowalski¹, Emily Banasiak¹, Grace Qian¹, Michael Diiorio¹, Tiffany Hsu¹, Michael Weinblatt⁴, Derrick Todd¹, Zachary Wallace³ and Jeffrey Sparks⁵, ¹Brigham and Women's Hospital, Boston, MA, ²Massachusetts General Hospital, Sale Creek, TN, ³Massachusetts General Hospital, Boston, MA, ⁴Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Advances in prevention, testing, and treatment of COVID-19 have contributed to less severe outcomes in the general population, but whether outcomes have improved for…
Abstract Number: L17 • ACR Convergence 2021
Additional Heterologous versus Homologous Booster Vaccination in Immunosuppressed Patients Without SARS-CoV-2 Antibody Seroconversion After Primary mRNA Vaccination: A Randomized Controlled Trial
Michael Bonelli¹, Daniel Mrak¹, Selma Tobudic¹, Daniela sieghart¹, Peter Mandl¹, barbara kornek¹, elisabeth simader¹, Maximilian Koblischke¹, Helga Radner¹, thomas perkmann¹, helmuth haslacher¹, Margareta Mayer¹, philipp hofer¹, Kurt Redlich², Emma Husar-Memmer³, Ruth Fritsch-Stork⁴, Renate Thalhammer¹, Karin Stiasny¹, Stefan Winkler¹, Josef Smolen¹, Judith Aberle¹, Markus Zeitlinger¹, Leonhard Heinz¹ and Daniel Aletaha⁵, ¹Medical University of Vienna, Vienna, Austria, ²Hietzing Hospital, Vienna, Austria, ³Hanusch Hospital, Vienna, Austria, ⁴Sigmund Freud University, Utrecht, Netherlands, ⁵Medical University Vienna, Wien, Austria
Background/Purpose: Severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2)-induced coronavirus disease 2019 (COVID-19) has led to exponentially rising mortality, particularly in immunosuppressed patients, who inadequately respond to…
Abstract Number: L18 • ACR Convergence 2021
Humoral and Cellular Immune Responses to a Second Dose of COVID-19 Vaccine BNT162b2 in People Receiving Methotrexate or Targeted Immunosuppression: A Cohort Study
Satveer K Mahil¹, Katie Bechman², Antony Raharja¹, Clara Domingo-Vila³, David Baudry¹, Matt Brown², Andrew Cope², Tejus Dasandi¹, Hataf Khan⁴, Thomas Lechmere⁴, Michael Malim⁴, Freya Meynell¹, Emily Pollock³, Kamila Sychowska³, Jonathan Barker¹, Sam Norton⁵, James Galloway², Katie Doores⁴, Timothy Tree³ and Catherine Smith¹, ¹St John’s Institute of Dermatology, Guy’s and St Thomas’ NHS Foundation Trust and King’s College London, London, ²Centre for Rheumatic Diseases, King's College London, London, ³Department of Immunobiology, Faculty of Life Sciences & Medicine, King's College London, London, United Kingdom, ⁴Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, United Kingdom, ⁵Psychology Department, Institute for Psychiatry Psychology & Neuroscience, King’s College London, London
Background/Purpose: COVID-19 vaccines have robust immunogenicity in the general population. Data on individuals with immune-mediated inflammatory diseases who are taking immunosuppressants remains limited. Our cohort…
Abstract Number: L01 • ACR Convergence 2021
Immunogenicity of mRNA COVID-19 Vaccines at 4 and 12 Weeks Post Full Vaccination in Patients with Inflammatory Rheumatic Diseases
Catherine Raptis¹, Diego Andrey², Christoph Berger³, Axel Finckh², Pierre Lescuyer², Adrian Ciurea⁴, Tanja Maletic¹, Christos Polysopoulos¹, Myriam Riek¹, Almut Scherer¹, Kim Lauper², Burkhard Moeller⁵, Judith Safford⁶, Sandra Schweizer⁷, Isabell von Loga¹, Nicolas Vuilleumier⁸ and Andrea Rubbert-Roth⁹, ¹SCQM Foundation, Zurich, Switzerland, ²Geneva University Hospital, Geneva, Switzerland, ³University Hospital Basel, Basel, Switzerland, ⁴University Hospital Zurich, Zrich, Switzerland, ⁵Inselspital - University Hospital Bern, Bern, Switzerland, ⁶RheumaCura Foundation, Zurich, Switzerland, ⁷Swiss League Against Rheumatism, Zurich, Switzerland, ⁸University Hospital of Geneva, Geneva, Switzerland, ⁹Kantonspital St Gallen, St.Gallen, Switzerland
Background/Purpose: Emerging evidence indicates that immunosuppressive therapies may result in reduced immunogenicity –and presumably reduced efficacy- following vaccination with mRNA COVID-19 vaccines but long-term data…
Abstract Number: L02 • ACR Convergence 2021
COVID-19 Vaccine in Immunosuppressed Adults with Autoimmune Diseases
Ines Colmegna¹, Mariana Useche¹, Emmanouil Rampakakis², Nathalie Amiable³, Emmanuelle Rollet-Labelle³, Louis Bessette⁴, Jo-Anne Costa⁴, Marc Dionne⁴, Mary-Ann Fitzcharles², Elizabeth Hazel², Deirdre McCormack², Laetitia Michou⁴, Pantelis Panopalis², Marc-Andre Langlois⁵, Sasha Bernatsky⁶ and Paul R. Fortin⁷, ¹The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ²McGill University Health Centre, Montreal, QC, Canada, ³Centre de Recherche du CHU de Quebec, Quebec, Canada, ⁴Universite Laval, Quebec, QC, Canada, ⁵University of Ottawa, Ottawa, ON, Canada, ⁶McGill University, Montreal, QC, Canada, ⁷CHU de Quebec - Universite Laval, Quebec, Canada
Background/Purpose: Immunocompromised conditions and/or a history of autoimmune disease were exclusion criteria of the initial SARS-CoV-2 vaccines clinical trials. We assessed the safety and immunogenicity…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].